

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

WORLD HEALTH ORGANIZATION
TECHNICAL REPORT SERIES

No. 413

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Twenty-first Report

WORLD HEALTH ORGANIZATION

GENEVA

1969

© World Health Organization 1969

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization.

For rights of reproduction or translation of WHO publications *in toto*, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

CONTENTS

	Page
GENERAL	7

PHARMACOLOGICAL

Antibiotics

1. Viomycin	10
2. Rolitetraeycline	10
3. Colistin	11
4. Colistin methane sulfonate	11
5. Chlortetraeycline	11
6. Gentamycin	12
7. Lymecycline	12
8. Methacycline	12
9. Polymyxin B	13
10. Neomycins B and C	13
11. Heptaene antibiotics	13
12. Nisin and subtilin	14
13. Penicillin	14
14. Phenoxymethylpenicillin	14
15. Pecilocin	14
16. Anisomycin, fumagillin and puromycin	15
17. Other antibiotics	15

Hormones and enzymes

18. New nomenclature of international standards (and reference preparations) for hormones	15
19. Human growth hormone	16
20. Human insulin	16

	Page
21. Lysine vasopressin	16
22. Angiotensins and renins	17
23. Erythropoietin	17
24. Heparins	17
25. Urokinase	18
26. Antihaemophilic factor (factor VIII)	18

IMMUNOLOGICAL

Antigens

27. Anthrax vaccine (for human use)	18
28. Anthrax vaccine (live—for veterinary use)	18
29. BCG vaccine	19
30. Rabies vaccine	19
31. Cholera vaccine	19
32. Typhoid vaccine	19
33. Newcastle disease vaccine (live)	20
34. Influenza virus haemagglutinin (type A)	20
35. Plague vaccine	20
36. Cholera antigens	21

Antibodies

37. Anti- <i>Brucella abortus</i> serum	21
38. Anti- <i>Mycoplasma gallisepticum</i> serum	21
39. Anti-Rh ₀ (anti-D) complete blood-typing serum	22
40. Anti-toxoplasma serum	22
41. Human auto-immune antibodies	22
42. Anti-Newcastle-disease serum	22
43. Rheumatoid arthritis serum	22
44. Human normal serum	23

MISCELLANEOUS

45. Interferons	23
---------------------------	----

	Page
BIOLOGICAL REFERENCE REAGENTS	
46. Anti-trichinella human serum	23
47. Cholera agglutinating sera	24
48. Anti- <i>Leptospira</i> sera	24
49. Respiratory virus and <i>Mycoplasma pneumoniae</i> antisera	24
REQUIREMENTS FOR BIOLOGICAL SUBSTANCES	
50. Requirements for cholera vaccine	24
51. Requirements for immune sera of animal origin	25
52. Seed culture of <i>Salmonella typhi</i>	25
53. Seed culture of <i>Bacillus anthracis</i>	25
54. Requirements for rabies vaccine	25
55. Other requirements for biological substances	26
56. Non-human primates for biomedical use	26
57. Services to national control laboratories for biological products	26
ANNEXES	
Annex 1. Requirements for cholera vaccine (Requirements for biological substances No. 4), revised 1968	27
Annex 2. Requirements for immune sera of animal origin (Requirements for biological substances No. 18)	45
Annex 3. Requirements for biological substances (general description and list of published documents)	61
Annex 4. International biological standards, and international biological reference preparations, 1969	63
Annex 5. International biological reference reagents	94
Annex 6. Proposed international biological standards, international biological reference preparations and international biological reference reagents.	100
Annex 7. Discontinued international biological standards	103
INDEX	105

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 30 September to 5 October, 1968

Members :

- Dr N. K. Dutta, Director, Haffkine Institute, Bombay, India
Dr A. Lafontaine, Director, Institute of Hygiene and Epidemiology, Brussels, Belgium
Mr J. W. Lightbown, Division of Biological Standards, National Institute for Medical Research, London, England (*Chairman*)
Professor B. Lunenfeld, Director, Institute of Endocrinology, Tel-Hashomer Government Hospital and Bar Ilan University, Tel-Hashomer, Israel
Dr R. Murray, Director, Division of Biologics Standards, National Institutes of Health, Bethesda, Md., USA
Dr J. D. van Ramshorst, Chief, Laboratory of Biological Standardization, Rijks Instituut voor de Volksgezondheid, Utrecht, Holland (*Rapporteur*)
Dr J. Spaun, Deputy Director, Department of Biological Standardization, Statens Seruminstitut, Copenhagen, Denmark
Mr J. R. Thayer, Viral Products Section, National Biological Standards Laboratory, Parkville, Victoria, Australia (*Vice-Chairman*)
Dr G. V. Vygodčikov, Head, Department, Gamaleja Institute of Epidemiology and Microbiology, Moscow, USSR
Dr G. R. Zahnd, Chargé de Recherches, Policlinique universitaire de Médecine, Geneva, Switzerland

Representatives of other organizations :

Food and Agriculture Organization of the United Nations :

- Mr I. Davidson, Central Veterinary Laboratory, Weybridge, Surrey, England

International Atomic Energy Agency :

- Dr F. Antoni, Radiation Biology, International Atomic Energy Agency, Vienna, Austria

Secretariat :

- Dr D. R. Bangham, Director, Division of Biological Standards, National Institute for Medical Research, London, England (*Consultant*)
Professor D. G. Evans, London School of Hygiene and Tropical Medicine, London, England (*Consultant*)
Mr E. C. Hulse, Director, Department of Biological Products and Standards, Central Veterinary Laboratory, Weybridge, Surrey, England (*Consultant*)
Dr A. N. Klimov, Director, Division of Biomedical Sciences, WHO
Dr P. Krag, Director, Department of Biological Standardization, Statens Seruminstitut, Copenhagen, Denmark (*Consultant*)
Dr A. S. Otschoorn, Chief Medical Officer, Biological Standardization, WHO (*Secretary*)
Professor A. E. Wilhelmi, Department of Biochemistry, Woodruff Medical Center of Emory University, Atlanta, Ga., USA (*Consultant*)
Dr W. W. Wright, Acting Deputy Director, Division of Pharmaceutical Sciences, Bureau of Science, Food and Drug Administration, Washington, D.C., USA (*Consultant*)

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Twenty-first Report

The WHO Expert Committee on Biological Standardization met in Geneva from 30 September to 5 October 1968. Dr P. Dorolle, Deputy Director-General, welcomed the members of the Committee on behalf of the Director-General. He also welcomed the representative of the Food and Agriculture Organization of the United Nations and the representative of the International Atomic Energy Agency.

The Deputy Director-General stated that this twenty-first meeting of the WHO Expert Committee on Biological Standardization should be regarded as an important anniversary because it brought to mind the long traditions of the Committee and the useful service it rendered. He pointed out that the subjects covered by the programme of biological standardization were increasing in scope and complexity, particularly in recent years. It was inevitable, therefore, that certain tasks of evident importance had to be left aside so that the Committee could undertake others of higher priority in relation to the overall programme of the World Health Organization.

In addition to the establishment of international standards for use as references in biological assays, the Expert Committee had in recent years been given the responsibility for reviewing and approving the various sets of requirements for biological substances formulated by the WHO Secretariat. These had proved of great value to Member States, especially when control activities over biological products were being developed.

GENERAL

The Committee gave further consideration to the problems arising from the estimation of hormones by the techniques of immunoassay, discussed in its twentieth report.¹ The information that had since been collected by the WHO Secretariat was taken into account.

¹ *Wld Hlth Org. techn. Rep. Ser.*, 1968, **384**, 8.

The Committee was informed that for various reasons related to the species specificity of hormones, it would be desirable for international standards and reference preparations of protein and polypeptide hormones to be named so as to indicate the species of origin of the preparations and the use for which they were intended, i.e., for immunoassay or for bioassay. The Committee therefore recommended that this principle should be followed in the future and also decided to rename the existing international standards and reference preparations of hormones for bioassay accordingly.

The Committee was also informed that immunoassays of hormones had important implications in clinical medicine and research as well as in the national control of hormone preparations used in therapy. There was a need, therefore, to establish international standards as early as possible. Since the collaborative assays necessary for the establishment of international standards would inevitably take considerable time, the Committee agreed that suitable preparations could meanwhile serve usefully as international reference preparations. The Committee stressed, however, the importance of ensuring that minimum criteria for such preparations are satisfied before their establishment even as international reference preparations. The Committee requested the WHO Secretariat to obtain advice from appropriate experts on the minimum criteria desirable for this purpose in respect of each preparation. In addition, it was essential that all information regarding a particular preparation and the results of tests made should be circulated to interested workers so that any observations or suggestions that they wished to make could also be taken into account by the Committee when deciding whether or not the criteria had been fulfilled.

The Committee discussed various possible ways of specifying potency as determined by immunoassay and decided that it was advisable not to depart from the practice of specifying potency in international units. The international unit for an international standard (or reference preparation) used in immunoassay should be defined in the same way as the international unit for an international standard used in bioassay, i.e., as the activity contained in a stated amount (by weight) of the international standard (or reference preparation) for immunoassay.

In defining such an international unit it would be desirable to make this as nearly as possible equal to an existing international unit for bioassay, even when the latter is for a standard originating from another species. When a standard for immunoassay is replaced, the international unit should be defined by comparing the new standard with the previous standard by immunoassay. When a standard for immunoassay is the first standard established for a hormone, and a standard for bioassay for the hormone of the same species of origin is introduced later, the unit for bioassay should be assigned by bioassay against the existing standard for immunoassay. Ideally, for a hormone of any given species of origin the unit for the standard

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30861

